journal
https://read.qxmd.com/read/37732466/combined-treatment-of-human-induced-pluripotent-stem-cell-derived-cardiomyocytes-and-endothelial-cells-regenerate-the-infarcted-heart-in-mice-and-non-human-primates
#1
JOURNAL ARTICLE
Yu-Che Cheng, Marvin L Hsieh, Chen-Ju Lin, Cindy M C Chang, Ching-Ying Huang, Riley Puntney, Amy Wu Moy, Chien-Yu Ting, Darien Zhing Herr Chan, Martin W Nicholson, Po-Ju Lin, Hung-Chih Chen, Gina C Kim, Jianhua Zhang, Jennifer Coonen, Puja Basu, Heather A Simmons, Yen-Wen Liu, Timothy A Hacker, Timothy J Kamp, Patrick C H Hsieh
BACKGROUND: Remuscularization of the mammalian heart can be achieved after cell transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). However, several hurdles remain before implementation into clinical practice. Poor survival of the implanted cells is related to insufficient vascularization, and the potential for fatal arrhythmogenesis is associated with the fetal cell-like nature of immature CMs. METHODS: We generated 3 lines of hiPSC-derived endothelial cells (ECs) and hiPSC-CMs from 3 independent donors and tested hiPSC-CM sarcomeric length, gap junction protein, and calcium-handling ability in coculture with ECs...
September 21, 2023: Circulation
https://read.qxmd.com/read/37732457/oral-anticoagulation-use-and-left-atrial-appendage-occlusion-in-laaos-iii
#2
JOURNAL ARTICLE
Stuart J Connolly, Jeff S Healey, Emilie P Belley-Cote, Kumar Balasubramanian, Domenico Paparella, Katheryn Brady, Wilko Reents, Bernhard C Danner, P J Devereaux, Mukul Sharma, Chinthanie Ramasundarahettige, Salim Yusuf, Richard P Whitlock
BACKGROUND: LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation undergoing cardiac surgery. This article examines the effect of LAA occlusion on stroke reduction according to variation in the use of oral anticoagulants (OACs). METHODS: Information regarding OAC use was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks of hospital discharge, 1 and 2 years after randomization, evaluated the effect of LAA occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use...
September 21, 2023: Circulation
https://read.qxmd.com/read/37732454/existing-nongated-ct-coronary-calcium-predicts-operative-risk-in-patients-undergoing-noncardiac-surgeries-encores
#3
JOURNAL ARTICLE
Daniel Y Choi, Dena Hayes, Samuel D Maidman, Nehal Dhaduk, Jill E Jacobs, Anna Shmukler, Jeffrey S Berger, Germaine Cuff, David Rehe, Mitchell Lee, Robert Donnino, Nathaniel R Smilowitz
BACKGROUND: Preoperative cardiovascular risk stratification before noncardiac surgery is a common clinical challenge. Coronary artery calcium scores from ECG-gated chest computed tomography (CT) imaging are associated with perioperative events. At the time of preoperative evaluation, many patients will not have had ECG-gated CT imaging, but will have had nongated chest CT studies performed for a variety of noncardiac indications. We evaluated relationships between coronary calcium severity estimated from previous nongated chest CT imaging and perioperative major clinical events (MCE) after noncardiac surgery...
September 21, 2023: Circulation
https://read.qxmd.com/read/37732422/cardiovascular-imaging-in-contemporary-cardio-oncology-a-scientific-statement-from-the-american-heart-association
#4
REVIEW
Daniel Addison, Tomas G Neilan, Ana Barac, Marielle Scherrer-Crosbie, Tochi M Okwuosa, Juan C Plana, Kerryn W Reding, Viviany R Taqueti, Eric H Yang, Vlad G Zaha
Advances in cancer therapeutics have led to dramatic improvements in survival, now inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Advances in cardiovascular imaging have solidified the critical role for robust methods for detecting, monitoring, and prognosticating cardiac risk among patients with cancer. However, decentralized evaluations have led to a lack of consensus on the optimal uses of imaging in contemporary cancer treatment (eg, immunotherapy, targeted, or biological therapy) settings...
September 21, 2023: Circulation
https://read.qxmd.com/read/37721051/dna-damage-and-nuclear-morphological-changes-in-cardiac-hypertrophy-are-mediated-by-snrk-through-actin-depolymerization
#5
JOURNAL ARTICLE
Paulina Stanczyk, Yuki Tatekoshi, Jason S Shapiro, Krithika Nayudu, Yihan Chen, Zachary Zilber, Matthew Schipma, Adam De Jesus, Amir Mahmoodzadeh, Ashley Akrami, Hsiang-Chun Chang, Hossein Ardehali
BACKGROUND: Proper nuclear organization is critical for cardiomyocyte function, because global structural remodeling of nuclear morphology and chromatin structure underpins the development and progression of cardiovascular disease. Previous reports have implicated a role for DNA damage in cardiac hypertrophy; however, the mechanism for this process is not well delineated. AMPK (AMP-activated protein kinase) family of proteins regulates metabolism and DNA damage response (DDR). Here, we examine whether a member of this family, SNRK (SNF1-related kinase), which plays a role in cardiac metabolism, is also involved in hypertrophic remodeling through changes in DDR and structural properties of the nucleus...
September 18, 2023: Circulation
https://read.qxmd.com/read/37721036/mental-health-conditions-among-children-and-adolescents-with-congenital-heart-disease-a-danish-population-based-cohort-study
#6
JOURNAL ARTICLE
Kimberley G Miles, Dóra Körmendiné Farkas, Kristina Laugesen, Henrik Toft Sørensen, Nadine A Kasparian, Nicolas Madsen
BACKGROUND: Despite the known mental health burden among children with congenital heart disease (CHD), the literature is constrained by a lack of comparison cohorts and population-based follow-up data. We examined the incidence of mental health conditions among children with CHD, relative to 3 comparison cohorts. METHODS: This population-based cohort study identified all children with CHD (<18 years of age; n=16 473) in Denmark from 1996 to 2017, through linkage of individual-level data across national registries...
September 18, 2023: Circulation
https://read.qxmd.com/read/37721023/2023-american-heart-association-focused-update-on-the-management-of-patients-with-cardiac-arrest-or-life-threatening-toxicity-due-to-poisoning-an-update-to-the-american-heart-association-guidelines-for-cardiopulmonary-resuscitation-and-emergency-cardiovascular
#7
REVIEW
Eric J Lavonas, Peter D Akpunonu, Ann M Arens, Kavita M Babu, Dazhe Cao, Robert S Hoffman, Christopher O Hoyte, Maryann E Mazer-Amirshahi, Andrew Stolbach, Maude St-Onge, Trevonne M Thompson, George Sam Wang, Amber V Hoover, Ian R Drennan
In this focused update, the American Heart Association provides updated guidance for resuscitation of patients with cardiac arrest, respiratory arrest, and refractory shock due to poisoning. Based on structured evidence reviews, guidelines are provided for the treatment of critical poisoning from benzodiazepines, β-adrenergic receptor antagonists (also known as β-blockers), L-type calcium channel antagonists (commonly called calcium channel blockers), cocaine, cyanide, digoxin and related cardiac glycosides, local anesthetics, methemoglobinemia, opioids, organophosphates and carbamates, sodium channel antagonists (also called sodium channel blockers), and sympathomimetics...
September 18, 2023: Circulation
https://read.qxmd.com/read/37712257/angptl3-deficiency-and-risk-of-hepatic-steatosis
#8
JOURNAL ARTICLE
Laura D'Erasmo, Michele Di Martino, Thomas Neufeld, Tyler J Fraum, Chul Joo Kang, Kendall H Burks, Alessia Di Costanzo, Ilenia Minicocci, Simone Bini, Marianna Maranghi, Giovanni Pigna, Giancarlo Labbadia, Jie Zheng, Davide Fierro, Anna Montali, Fabrizio Ceci, Carlo Catalano, Nicholas O Davidson, Giuseppe Lucisano, Antonio Nicolucci, Marcello Arca, Nathan O Stitziel
BACKGROUND: ANGPTL3 (angiopoietin-like 3 protein) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3. METHODS: The authors recruited participants with ANGPTL3 deficiency related to ANGPTL3 loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St...
September 15, 2023: Circulation
https://read.qxmd.com/read/37712250/elimination-of-camkii%C3%AE-autophosphorylation-by-crispr-cas9-base-editing-improves-survival-and-cardiac-function-in-heart-failure-in-mice
#9
JOURNAL ARTICLE
Simon Lebek, Xurde M Caravia, Francesco Chemello, Wei Tan, John R McAnally, Kenian Chen, Lin Xu, Ning Liu, Rhonda Bassel-Duby, Eric N Olson
BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca2+ /calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders. METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ...
September 15, 2023: Circulation
https://read.qxmd.com/read/37698007/implementation-of-prevention-science-to-eliminate-health-care-inequities-in-achieving-cardiovascular-health-a-scientific-statement-from-the-american-heart-association
#10
REVIEW
Anandita Agarwala, Jaideep Patel, Janna Stephens, Shamarial Roberson, Jewel Scott, Theresa Beckie, Elizabeth A Jackson
Prevention of cardiovascular and related diseases is foundational to attaining ideal cardiovascular health to improve the overall health and well-being of individuals and communities. Social determinants of health and health care inequities adversely affect ideal cardiovascular health and prevention of disease. Achieving optimal cardiovascular health in an effective and equitable manner requires a coordinated multidisciplinary and multilayered approach. In this scientific statement, we examine barriers to ideal cardiovascular health and its related conditions in the context of leveraging existing resources to reduce health care inequities and to optimize the delivery of preventive cardiovascular care...
September 12, 2023: Circulation
https://read.qxmd.com/read/37681341/associations-of-apixaban-dose-with-safety-and-effectiveness-outcomes-in-patients-with-atrial-fibrillation-and-severe-chronic-kidney-disease
#11
JOURNAL ARTICLE
Yunwen Xu, Alex R Chang, Lesley A Inker, Mara McAdams-DeMarco, Morgan E Grams, Jung-Im Shin
BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation. Optimal apixaban dosing in chronic kidney disease remains unknown. METHODS: With the use of deidentified electronic health record data from the Optum Labs Data Warehouse, patients with atrial fibrillation and chronic kidney disease stage 4/5 initiating apixaban between 2013 and 2021 were identified...
September 8, 2023: Circulation
https://read.qxmd.com/read/37681315/changes-in-cardiovascular-spending-care-utilization-and-clinical-outcomes-associated-with-participation-in-bundled-payments-for-care-improvement-advanced
#12
JOURNAL ARTICLE
Sukruth A Shashikumar, Jie Zheng, E John Orav, Arnold M Epstein, Karen E Joynt Maddox
BACKGROUND: Bundled Payments for Care Improvement Advanced (BPCI-A) is a Medicare initiative that aims to incentivize reductions in spending for episodes of care that start with a hospitalization and end 90 days after discharge. Cardiovascular disease, an important driver of Medicare spending, is one of the areas of focus BPCI-A. It is unknown whether BPCI-A is associated with spending reductions or quality improvements for the 3 cardiovascular medical events or 5 cardiovascular procedures in the model...
September 8, 2023: Circulation
https://read.qxmd.com/read/37681311/clonal-hematopoiesis-in-clinical-and-experimental-heart-failure-with-preserved-ejection-fraction
#13
JOURNAL ARTICLE
Jesse Cochran, Yoshimitsu Yura, Mark C Thel, Heather Doviak, Ariel H Polizio, Yuka Arai, Yohei Arai, Keita Horitani, Eunbee Park, Nicholas W Chavkin, Anupreet Kour, Soichi Sano, Nitin Mahajan, Megan Evans, Mahalia Huba, Nadia Martinez Naya, Hanna Sun, Youngho Ban, Karen K Hirschi, Stefano Toldo, Antonio Abbate, Todd E Druley, Frederick L Ruberg, Mathew S Maurer, Justin A Ezekowitz, Jason R B Dyck, Kenneth Walsh
BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model...
September 8, 2023: Circulation
https://read.qxmd.com/read/37671551/cost-effectiveness-of-vericiguat-in-patients-with-heart-failure-with-reduced-ejection-fraction-the-victoria-randomized-clinical-trial
#14
JOURNAL ARTICLE
Derek S Chew, Yanhong Li, Robert Bigelow, Patricia A Cowper, Kevin J Anstrom, Melanie R Daniels, Linda Davidson-Ray, Adrian F Hernandez, Christopher M O'Connor, Paul W Armstrong, Daniel B Mark
BACKGROUND: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0...
September 6, 2023: Circulation
https://read.qxmd.com/read/37646159/principles-for-health-information-collection-sharing-and-use-a-policy-statement-from-the-american-heart-association
#15
REVIEW
Kayte Spector-Bagdady, Antonis A Armoundas, Rima Arnaout, Jennifer L Hall, Brooke Yeager McSwain, Joshua W Knowles, W Nicholson Price, Danda B Rawat, Barbara Riegel, Tracy Y Wang, Kevin Wiley, Mina K Chung
The evolution of the electronic health record, combined with advances in data curation and analytic technologies, increasingly enables data sharing and harmonization. Advances in the analysis of health-related and health-proxy information have already accelerated research discoveries and improved patient care. This American Heart Association policy statement discusses how broad data sharing can be an enabling driver of progress by providing data to develop, test, and benchmark innovative methods, scalable insights, and potential new paradigms for data storage and workflow...
August 30, 2023: Circulation
https://read.qxmd.com/read/37641966/rare-variant-genetics-and-dilated-cardiomyopathy-severity-the-dcm-precision-medicine-study
#16
JOURNAL ARTICLE
Mark Hofmeyer, Garrie J Haas, Elizabeth Jordan, Jinwen Cao, Evan Kransdorf, Gregory A Ewald, Alanna A Morris, Anjali Owens, Brian Lowes, Douglas Stoller, W H Wilson Tang, Sonia Garg, Barry H Trachtenberg, Palak Shah, Salpy V Pamboukian, Nancy K Sweitzer, Matthew T Wheeler, Jane E Wilcox, Stuart Katz, Stephen Pan, Javier Jimenez, Frank Smart, Jessica Wang, Stephen S Gottlieb, Daniel P Judge, Charles K Moore, Gordon S Huggins, Daniel D Kinnamon, Hanyu Ni, Ray E Hershberger
BACKGROUND: Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied. METHODS: We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort...
August 29, 2023: Circulation
https://read.qxmd.com/read/37638968/edoxaban-for-12-months-versus-3-months-in-cancer-patients-with-isolated-distal-deep-vein-thrombosis-onco-dvt-study-an-open-label-multicenter-randomized-clinical-trial
#17
JOURNAL ARTICLE
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yuichiro Minami, Yoshito Ogihara, Kaoru Dohi, Masashi Fujita, Tatsuya Nishikawa, Nobutaka Ikeda, Go Hashimoto, Kazunori Otsui, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa, Takeshi Kimura
Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with isolated distal DVT, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment...
August 28, 2023: Circulation
https://read.qxmd.com/read/37638389/identification-of-human-ventricular-tachycardia-demarcated-by-fixed-lines-of-conduction-block-in-a-3-dimensional-hyperboloid-circuit
#18
JOURNAL ARTICLE
Takuro Nishimura, Nathan Shatz, Peter Weiss, Michael Zawaneh, Rong Bai, Andrew D Beaser, Gaurav A Upadhyay, Zaid A Aziz, Hemal M Nayak, Dalise Y Shatz, Shinsuke Miyazaki, Masahiko Goya, Tetsuo Sasano, Wilber Su, Michael Raiman, Roderick Tung
BACKGROUND: The circuit boundaries for reentrant ventricular tachycardia (VT) have been historically conceptualized within a 2-dimensional (2D) construct, with their fixed or functional nature unresolved. This study aimed to examine the correlation between localized lines of conduction block (LOBs) evident during baseline rhythm with lateral isthmus boundaries that 3-dimensionally constrain the VT isthmus as a hyperboloid structure. METHODS: A total of 175 VT activation maps were correlated with isochronal late activation maps during baseline rhythm in 106 patients who underwent catheter ablation for scar-related VT from 3 centers (42% nonischemic cardiomyopathy)...
August 28, 2023: Circulation
https://read.qxmd.com/read/37634187/cardiac-magnetic-resonance-imaging-versus-computed-tomography-to-guide-transcatheter-aortic-valve-replacement-tavr-cmr-a-randomized-open-label-non-inferiority-trial
#19
JOURNAL ARTICLE
Martin Reindl, Ivan Lechner, Magdalena Holzknecht, Christina Tiller, Priscilla Fink, Fritz Oberhollenzer, Sebastian von der Emde, Mathias Pamminger, Felix Troger, Christian Kremser, Elisabeth Laßnig, Kathrin Danninger, Ronald K Binder, Hanno Ulmer, Christoph Brenner, Gert Klug, Axel Bauer, Bernhard Metzler, Agnes Mayr, Sebastian Johannes Reinstadler
Background: Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, as a sizable proportion of TAVR candidates have chronic kidney disease (CKD), the use of iodinated contrast media is a limitation. Cardiac magnetic resonance (CMR) is a promising alternative, yet randomized data comparing the effectiveness of CMR- versus CT-guided TAVR are lacking. Methods: An investigator-initiated, prospective, randomized, open-label, non-inferiority trial was conducted at two Austrian heart centers...
August 27, 2023: Circulation
https://read.qxmd.com/read/37634130/safety-of-switching-from-a-vitamin-k-antagonist-to-a-non-vitamin-k-antagonist-oral-anticoagulant-in-frail-older-patients-with-atrial-fibrillation-results-of-the-frail-af-randomized-controlled-trial
#20
JOURNAL ARTICLE
Linda P T Joosten, Sander van Doorn, Peter M van de Ven, Bart T G Köhlen, Melchior C Nierman, Huiberdina L Koek, Martin E W Hemels, Menno V Huisman, Marieke Kruip, Laura M Faber, Nynke M Wiersma, Wim F Buding, Rob Fijnheer, Henk J Adriaansen, Kit C Roes, Arno W Hoes, Frans H Rutten, Geert-Jan Geersing
Background: There is ambiguity whether frail patients with atrial fibrillation (AF) managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). Methods: We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older AF patients living with frailty (age ≥75 years plus a Groningen Frailty Indicator (GFI) score ≥3) were randomized to switch from INR-guided VKA treatment to a NOAC or to continued VKA treatment. Patients with a glomerular filtration rate <30 mL/min/1...
August 27, 2023: Circulation
journal
journal
20069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.